These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 308621)

  • 41. A novel neurodevelopmental syndrome responsive to 5-hydroxytryptophan and carbidopa.
    Ramaekers VT; Senderek J; Häusler M; Häring M; Abeling N; Zerres K; Bergmann C; Heimann G; Blau N
    Mol Genet Metab; 2001 Jun; 73(2):179-87. PubMed ID: 11386854
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Hypoxanthine-guanine phosphoribosyltransferase: characteristics of the mutant enzyme in erythrocytes from patients with the Lesch-Nyhan syndrome.
    Arnold WJ; Meade JC; Kelley WN
    J Clin Invest; 1972 Jul; 51(7):1805-12. PubMed ID: 4624352
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Serotonin-GABA treatment is hypothesized for self-injury in Lesch-Nyhan syndrome.
    Gedye A
    Med Hypotheses; 1992 Aug; 38(4):325-8. PubMed ID: 1491633
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Current trends in the treatment of self-injurious behavior.
    Singh NN
    Adv Pediatr; 1981; 28():377-440. PubMed ID: 7041563
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effects of L-5-hydroxytryptophan in autistic children.
    Sverd J; Kupietz SS; Winsberg BG; Hurwic MJ; Becker L
    J Autism Child Schizophr; 1978 Jun; 8(2):171-80. PubMed ID: 307546
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Letter: Treatment of post-anoxic intention myoclonus.
    Van Woert MH; Sethy VH
    Lancet; 1974 Jun; 1(7869):1285. PubMed ID: 4134164
    [No Abstract]   [Full Text] [Related]  

  • 47. Self-mutilation behaviour in Lesch-Nyhan syndrome.
    Cauwels RG; Martens LC
    J Oral Pathol Med; 2005 Oct; 34(9):573-5. PubMed ID: 16138897
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Self mutilation behavior and uric acid metabolism disorders in an adult (Lesch-Nyhan syndrome?)].
    Eyssette M; Setiey A; Aimard G; Devic M
    Rev Neurol (Paris); 1972 Feb; 126(2):144-9. PubMed ID: 4654781
    [No Abstract]   [Full Text] [Related]  

  • 49. [Some up-to-date ideas on the Lesch-Nyhan syndrome. Apropos of a case].
    Champagne M; Cudzinowski L; Mascrès C
    J Dent Que; 1980; 17():45-8. PubMed ID: 6938555
    [No Abstract]   [Full Text] [Related]  

  • 50. [Treatment of high urinary xanthine excretion with increased amounts of allopurinol and with urate oxidase in a child with Lesch-Nyhan syndrome (author's transl)].
    Beyer P; Bieth R; Charton F; Himy G
    Ann Pediatr (Paris); 1980 Dec; 27(10):661-6. PubMed ID: 7212552
    [No Abstract]   [Full Text] [Related]  

  • 51. Levodopa combined with MK 486 (L-alpha methyldopahydrazine)--a peripheral decarboxylase inhibitor in Parkinson's disease.
    Andrews CJ; Somerville B
    Med J Aust; 1974 Mar; 1(12):429-32. PubMed ID: 4598384
    [No Abstract]   [Full Text] [Related]  

  • 52. Levodopa therapy in a Lesch-Nyhan disease patient: pathological, biochemical, neuroimaging, and therapeutic remarks.
    Serrano M; Pérez-Dueñas B; Ormazábal A; Artuch R; Campistol J; Torres RJ; García-Cazorla A
    Mov Disord; 2008 Jul; 23(9):1297-300. PubMed ID: 18528895
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Manipulation of brain serotonin in the treatment of myoclonus.
    Chadwick D; Jenner P; Harris R; Reynolds EH; Marsden CD
    Lancet; 1975 Sep; 2(7932):434-5. PubMed ID: 51240
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Behaviour therapy of autoagression with the Lesch-Nyhan-syndrome ( author's transl)].
    Jochmus I; Koch A; Wilhelmstroop-Meyer A
    Monatsschr Kinderheilkd (1902); 1977 Sep; 125(9):839-41. PubMed ID: 904645
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Safety and Efficacy of Botulinum Toxin in the Treatment of Self-Biting Behavior in Lesch-Nyhan Disease.
    Garcia-Romero MDM; Torres RJ; Garcia-Puig J; Pascual-Pascual SI
    Pediatr Neurol; 2022 Feb; 127():6-10. PubMed ID: 34891105
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A self-controllable mask with helmet to prevent self finger-mutilation in the Lesch-Nyhan syndrome.
    Eguchi S; Tokioka T; Motoyoshi A; Wakamura S
    Arch Phys Med Rehabil; 1994 Jun; 75(6):709-10. PubMed ID: 8002775
    [TBL] [Abstract][Full Text] [Related]  

  • 57. L-5-hydroxytryptophan in the treatment of anxiety disorders.
    Kahn RS; Westenberg HG
    J Affect Disord; 1985; 8(2):197-200. PubMed ID: 3157732
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Treatment of motor and behavioural symptoms in three Lesch-Nyhan patients with intrathecal baclofen.
    Pozzi M; Piccinini L; Gallo M; Motta F; Radice S; Clementi E
    Orphanet J Rare Dis; 2014 Dec; 9():208. PubMed ID: 25497359
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Self-mutilation in Lesch-Nyhan disease is caused by dopaminergic denervation.
    Goldstein M; Anderson LT; Reuben R; Dancis J
    Lancet; 1985 Feb; 1(8424):338-9. PubMed ID: 2857386
    [No Abstract]   [Full Text] [Related]  

  • 60. Behavioral contingencies and self-mutilation in Lesch-Nyhan disease.
    Anderson L; Dancis J; Alpert M
    J Consult Clin Psychol; 1978 Jun; 46(3):529-36. PubMed ID: 670495
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.